Most cited papers from BioSciCon (United States)

BioSciCon (United States)

What are the most cited papers from BioSciCon (United States)?

The most cited paper from BioSciCon (United States) is "Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older" (Lisa M. Dunkle, Ruvim Izikson, PETER A. PATRIARCA et al., 2017), with 293 citations. Next come "Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia" (205) and "Calorie restriction and cancer prevention: a mechanistic perspective" (130).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 14 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older Lisa M. Dunkle, Ruvim Izikson, PETER A. PATRIARCA et al. · New England Journal of Medicine	21 Jun 2017	293
2	Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia Bruce Lewis, William Matthai, Marc C. Cohen et al. · Catheterization and Cardiovascular Interventions	30 Sep 2002	205
3	Calorie restriction and cancer prevention: a mechanistic perspective Stephen David Hursting, Sarah M. Dunlap, Nikki Ann Ford et al. · Cancer & Metabolism Open access	7 Mar 2013	130
4	Effects of Argatroban Therapy, Demographic Variables, and Platelet Count on Thrombotic Risks in Heparin-Induced Thrombocytopenia Bruce Lewis, Diane E. Wallis, Marcie J. Hursting et al. · CHEST Journal	Jun 2006	122
5	Argatroban Anticoagulation in Patients With Acute Ischemic Stroke (ARGIS-1) Marian P. LaMonte, Marshall Nash, David Z. Wang et al. · Stroke	24 May 2004	117
6	Cell cross-contamination in cell cultures: The silent and neglected danger Olivera Marković, Nenad S. Markovic · In Vitro Cellular & Developmental Biology - Animal	1998	110
7	Platelet Factor 4/Heparin Antibodies in Blood Bank Donors Marcie J. Hursting, Poulomi J. Pai, Julianna E. McCracken et al. · American Journal of Clinical Pathology Open access	20 Oct 2010	88
8	Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia Jeanine M. Walenga, Sarfraz Ahmad, Debra Hoppensteadt et al. · Thrombosis Research	Mar 2002	87
9	Argatroban Therapy in Heparin-Induced Thrombocytopenia With Hepatic Dysfunction Robert L. Levine, Marcie J. Hursting, David A. McCollum · CHEST Journal	May 2006	87
10	Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open‐label, safety, efficacy, and pharmacokinetic study Guy A. Young, L Boshkov, Janice E. Sullivan et al. · Pediatric Blood & Cancer	5 Nov 2010	77
11	Transitioning from Argatroban to Warfarin Therapy in Patients with Heparin-induced Thrombocytopenia Marcie J. Hursting, Bruce Lewis, Donald E. Macfarlane · Clinical and Applied Thrombosis/Hemostasis Open access	Jul 2005	68
12	Transitioning from Argatroban to Warfarin in Heparin-Induced Thrombocytopenia: An Analysis of Outcomes in Patients with Elevated International Normalized Ratio (INR) John R. Bartholomew, Marcie J. Hursting · Journal of Thrombosis and Thrombolysis	Jun 2005	64
13	Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age Lisa M. Dunkle, Ruvim Izikson, PETER A. PATRIARCA et al. · The Journal of Infectious Diseases	6 Sep 2017	59
14	Argatroban Anticoagulation in Pediatric Patients Marcie J. Hursting, Jeffrey W. Dubb, Catherine N Verme-Gibboney · Journal of Pediatric Hematology/Oncology	28 Dec 2005	59
15	Heparin-induced Thrombocytopenia, a Prothrombotic Disease Jerrold H. Levy, Marcie J. Hursting · Hematology/Oncology Clinics of North America	25 Jan 2007	52
16	Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia Louis M. Guzzi, David A. McCollum, Marcie J. Hursting · Journal of Thrombosis and Thrombolysis	13 Nov 2006	49
17	Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia Jerrold H. Levy, Kenichi A. Tanaka, Marcie J. Hursting · Anesthesia & Analgesia	17 Aug 2007	46
18	Argatroban Anticoagulation in Intensive Care Patients: Effects of Heart Failure and Multiple Organ System Failure Susan M. Begelman, Sarkis B. Baghdasarian, Inderpal Singh et al. · Journal of Intensive Care Medicine	12 Aug 2008	46
19	Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results Gowthami M. Arepally, Marcie J. Hursting · Journal of Thrombosis and Thrombolysis Open access	27 Mar 2008	45
20	Argatroban Anticoagulation in Renal Dysfunction: A Literature Analysis Marcie J. Hursting, Patrick T. Murray · Nephron Clinical Practice	18 Jun 2008	45
21	How Frequently Is Venous Thromboembolism in Heparin-Treated Patients Associated With Heparin-Induced Thrombocytopenia? Robert L. Levine, David A. McCollum, Marcie J. Hursting · CHEST Journal	Sep 2006	43
22	Argatroban for Suspected Heparin-Induced Thrombocytopenia: Contemporary Experience at a Large Teaching Hospital Sandeep Kodityal, Hoang-Phuong Nguyen, Amith Kodityal et al. · Journal of Intensive Care Medicine	Mar 2006	38
23	Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents John L. Francis, Marcie J. Hursting · Blood Coagulation & Fibrinolysis	3 May 2005	36
24	Argatroban Anticoagulation in Obese Versus Nonobese Patients: Implications for Treating Heparin‐induced Thrombocytopenia Lawrence E. Rice, Marcie J. Hursting, G. Mark Baillie et al. · The Journal of Clinical Pharmacology	20 Jun 2007	34
25	Heparin–platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study Robert L. Levine, Georgene W. Hergenroeder, John L. Francis et al. · Journal of Thrombosis and Thrombolysis	12 Nov 2009	34
26	Argatroban Therapy for Heparin-Induced Thrombocytopenia in Acutely Ill Patients Anthony W. Gray, Diane E. Wallis, Marcie J. Hursting et al. · Clinical and Applied Thrombosis/Hemostasis	Oct 2007	34
27	Insulin access to skeletal muscle is impaired during the early stages of diet‐induced obesity Josiane L. Broussard, Ana Valeria Castro, Malini S. Iyer et al. · Obesity Open access	29 Aug 2016	33
28	Phase Angle as a Marker of Muscular Strength in Breast Cancer Survivors Catarina N. Matias, Joana Cavaco‐Silva, Mafalda Reis et al. · International Journal of Environmental Research and Public Health Open access	21 Jun 2020	32
29	Reduced Argatroban Doses After Coronary Artery Bypass Graft Surgery William D. Hoffman, Yvonne Czyz, David A. McCollum et al. · Annals of Pharmacotherapy	26 Feb 2008	31
30	Liposome polymerase chain reaction assay for the sub-attomolar detection of cholera toxin and botulinum neurotoxin type A Jeffrey T. Mason, Lixin Xu, Zong‐Mei Sheng et al. · Nature Protocols	Nov 2006	31
31	Valuation of Continuously Monitored Double Barrier Options and Related Securities Mitya Boyarchenko, Sergei Zakharovich Levendorskii · SSRN Electronic Journal PreprintOpen access	2009	31
32	Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia in Elderly Patients John R. Bartholomew, Carolynn E. Pietrangeli, Marcie J. Hursting · Drugs & Aging	2007	29
33	Reducing Harm Associated with Anticoagulation Marcie J. Hursting, Joseph Soffer · Drug Safety	2009	28
34	SINH-ACCELERATION: EFFICIENT EVALUATION OF PROBABILITY DISTRIBUTIONS, OPTION PRICING, AND MONTE CARLO SIMULATIONS Svetlana Boyarchenko, Sergei Zakharovich Levendorskii · International Journal of Theoretical and Applied Finance	8 Feb 2019	27
35	The Eigenfunction Expansion Method in Multi-Factor Quadratic Term Structure Models Nina Boyarchenko, Sergei Zakharovich Levendorskii · SSRN Electronic Journal PreprintOpen access	2006	27
36	New Efficient Versions of Fourier Transform Method in Applications to Option Pricing Svetlana Boyarchenko, Sergei Zakharovich Levendorskii · SSRN Electronic Journal PreprintOpen access	2011	26
37	Risk Factors for Major Bleeding in Patients With Heparin-induced Thrombocytopenia Treated With Argatroban: A Retrospective Study Marcie J. Hursting, Catherine N Verme-Gibboney · Journal of Cardiovascular Pharmacology	Dec 2008	26
38	Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition John G. Kelton, Marcie J. Hursting, Nancy M. Heddle et al. · Blood Coagulation & Fibrinolysis	Sep 2008	25
39	Compassionate Use: A Story of Ethics and Science in the Development of a New Drug William C. Buhles · Perspectives in biology and medicine	Jun 2011	24
40	Capture of genomic DNA on glass microscope slides Oliver Z. Nanassy, Paul V. Haydock, Michael W. Reed · Analytical Biochemistry Open access	25 Mar 2007	23
41	Practical Guide to Real Options in Discrete Time Svetlana Boyarchenko, Sergei Zakharovich Levendorskii · SSRN Electronic Journal PreprintOpen access	2004	23
42	Refined and Enhanced Fast Fourier Transform Techniques, with an Application to the Pricing of Barrier Options Mitya Boyarchenko, Sergei Zakharovich Levendorskii · SSRN Electronic Journal PreprintOpen access	2008	22
43	The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis Alan Kivitz, Liangwei Wang, Ilias Alevizos et al. · RMD Open Open access	Aug 2023	21
44	Efficient Laplace Inversion, Wiener-Hopf Factorization and Pricing Lookbacks Svetlana Boyarchenko, Sergei Zakharovich Levendorskii · SSRN Electronic Journal PreprintOpen access	2012	21
45	Heparin-Induced Thrombocytopenia in Patients Administered Heparin Solely for Hemodialysis Patrick T. Murray, Marcie J. Hursting · Renal Failure Open access	2006	21
46	Pricing of Discretely Sampled Asian Options Under Levy Processes Sergei Zakharovich Levendorskii, Jiayao Xie · SSRN Electronic Journal PreprintOpen access	2012	19
47	Argatroban Therapy in Women with Heparin-Induced Thrombocytopenia Ik‐Kyung Jang, Suzanne J. Baron, Marcie J. Hursting et al. · Journal of Women s Health	Jul 2007	19
48	Conformal Accelerations Method and Efficient Evaluation of Stable Distributions Svetlana Boyarchenko, Sergei Zakharovich Levendorskii · Acta Applicandae Mathematicae	27 Feb 2020	18
49	Fast and Accurate Pricing of Barrier Options Under Levy Processes Oleg E. Kudryavtsev, Sergei Zakharovich Levendorskii · SSRN Electronic Journal PreprintOpen access	2007	18
50	General Option Exercise Rules, with Applications to Embedded Options and Monopolistic Expansion Svetlana Boyarchenko, Sergei Zakharovich Levendorskii · SSRN Electronic Journal PreprintOpen access	2005	17

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.